三葉草生物-B(02197.HK)新冠候選疫苗獲追加最多3,690萬美元額外預算
三葉草生物-B(02197.HK)公布,於2021年4月及5月,公司與流行病防範創新聯盟(CEPI)接受公眾、私人、慈善及民間組織捐贈以資助開發針對新興傳染病的疫苗之獨立研究項目的基金會訂立兩份疫情應對資助協議。
據此及根據雙方同意的請求,CEPI同意對開發公司的COVID-19候選疫苗SCB-2019(CpG 1018加鋁佐劑)提供3.605億美元的資助。
CEPI已於2021年11月18日批准公司於2021年11月11日所提出對CEPI資助協議作出變更的請求,據此,考慮到評估三葉草生物的三聚體重組蛋白及已添加佐劑的COVID-19疫苗的保護效力及安全性研究(SPECTRA)II/III期關鍵性研究的積極結果,CEPI及公司互相同意在資助承諾的基礎上增加最多3,690萬美元的額外預算,以為SCB-2019(CpG 1018加鋁佐劑)臨床開發所需的以下SPECTRAII/III期臨床活動提供資金。
公司將利用CEPI的資金開發作為所有年齡組(兒童、青少年、成人及老人)主要接種疫苗的SCB-2019(CpG1018加鋁佐劑),並用於之前接受過以SCB-2019(CpG 1018加鋁佐劑)作為主要接種疫苗進行治療的既往感染個體及群體的潛在加強劑(同源加強劑)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.